Tags

Type your tag names separated by a space and hit enter

Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study.
Urology. 2006 May; 67(5):1038-42.U

Abstract

OBJECTIVES

To compare the efficacy and safety of intralesional interferon-alpha 2b combined with oral vitamin E or intralesional interferon-alpha 2b alone or oral vitamin E alone for the treatment of Peyronie's disease.

METHODS

From January 2000 to March 2002, a total of 30 consecutive men with Peyronie's disease were randomized prospectively into three different treatment groups. All the patients were assessed objectively with penile duplex Doppler ultrasonography for plaque size, location, and presence of calcification before and after treatment. Subjective data were obtained by querying about the improvement in penile pain and by using the "global efficacy question" for the assessment of the quality of sexual intercourse at the end of the study. A total of 5.0 x 10(6) U of interferon-alpha 2b was given once per week directly into the plaque for a period of 12 weeks. Patients received 400 IU of vitamin E orally twice daily for 6 months.

RESULTS

At the 6-month follow-up visit, we did not find any statistically significant changes in the objective parameters when compared with the initial findings in each group or among the three groups (P >0.05). We did not observe any clinically significant improvement in the subjective parameters among the three groups (P >0.05). However, all patients who were treated with interferon-alpha 2b experienced brief flu-like side effects.

CONCLUSIONS

Our findings indicate that 5 million units of intralesional interferon-alpha 2b injection therapy either alone or in combination with vitamin E does not appear to be clinically effective in the management of early stage Peyronie's disease compared with only oral vitamin E.

Authors+Show Affiliations

Department of Urology, University of Ankara School of Medicine, Ankara, Turkey.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16581113

Citation

Inal, Tansel, et al. "Effect of Intralesional Interferon-alpha 2b Combined With Oral Vitamin E for Treatment of Early Stage Peyronie's Disease: a Randomized and Prospective Study." Urology, vol. 67, no. 5, 2006, pp. 1038-42.
Inal T, Tokatli Z, Akand M, et al. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study. Urology. 2006;67(5):1038-42.
Inal, T., Tokatli, Z., Akand, M., Ozdiler, E., & Yaman, O. (2006). Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study. Urology, 67(5), 1038-42.
Inal T, et al. Effect of Intralesional Interferon-alpha 2b Combined With Oral Vitamin E for Treatment of Early Stage Peyronie's Disease: a Randomized and Prospective Study. Urology. 2006;67(5):1038-42. PubMed PMID: 16581113.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study. AU - Inal,Tansel, AU - Tokatli,Zafer, AU - Akand,Murat, AU - Ozdiler,Erol, AU - Yaman,Onder, Y1 - 2006/04/11/ PY - 2005/04/26/received PY - 2005/10/11/revised PY - 2005/11/02/accepted PY - 2006/4/4/pubmed PY - 2006/5/26/medline PY - 2006/4/4/entrez SP - 1038 EP - 42 JF - Urology JO - Urology VL - 67 IS - 5 N2 - OBJECTIVES: To compare the efficacy and safety of intralesional interferon-alpha 2b combined with oral vitamin E or intralesional interferon-alpha 2b alone or oral vitamin E alone for the treatment of Peyronie's disease. METHODS: From January 2000 to March 2002, a total of 30 consecutive men with Peyronie's disease were randomized prospectively into three different treatment groups. All the patients were assessed objectively with penile duplex Doppler ultrasonography for plaque size, location, and presence of calcification before and after treatment. Subjective data were obtained by querying about the improvement in penile pain and by using the "global efficacy question" for the assessment of the quality of sexual intercourse at the end of the study. A total of 5.0 x 10(6) U of interferon-alpha 2b was given once per week directly into the plaque for a period of 12 weeks. Patients received 400 IU of vitamin E orally twice daily for 6 months. RESULTS: At the 6-month follow-up visit, we did not find any statistically significant changes in the objective parameters when compared with the initial findings in each group or among the three groups (P >0.05). We did not observe any clinically significant improvement in the subjective parameters among the three groups (P >0.05). However, all patients who were treated with interferon-alpha 2b experienced brief flu-like side effects. CONCLUSIONS: Our findings indicate that 5 million units of intralesional interferon-alpha 2b injection therapy either alone or in combination with vitamin E does not appear to be clinically effective in the management of early stage Peyronie's disease compared with only oral vitamin E. SN - 1527-9995 UR - https://wwww.unboundmedicine.com/medline/citation/16581113/Effect_of_intralesional_interferon_alpha_2b_combined_with_oral_vitamin_E_for_treatment_of_early_stage_Peyronie's_disease:_a_randomized_and_prospective_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090-4295(05)01617-1 DB - PRIME DP - Unbound Medicine ER -